Life Science Nation Newsletter  | May 18,  2017  |  Issue 214

  The LSN Story   |   Investor Platform   |   Company Platform   |   RESI Conference   |   Fundraising Consulting
Life Science Investor Mandates (May 11  - May 17)
Makes Crossborder Investments in Digital Health
Invests in Medtech Worldwide
Seeks Drug Assets in Oncology, Immunology, Respiratory and Cardio
Invests in Medical Devices and Digital Health
In This Issue
Nature BioEntrepreneur Features LSN: Aligning Needs
LSN Services
Click to see investors that are a fit for your product and stage of development

Click here if you are a service provider and want to see a list of funded life science companies that are a fit for you

Click here if you want to receive free, targeted early stage dealflow for your life science investment firm

Free Copy of LSN's Book

LSN Videos
By Michael Quigley, VP of Market Research, LSN

RESI Partnering goes live on Monday, enabling fundraising life science executives and the investors who fund them to request meetings with one another on the basis of mutual fit. By getting into the system on day one you have the opportunity of being the first to request meetings, thus increasing your chances of being considered and getting the best meetings possible.

Powered by LSN's proprietary investor data, the RESI partnering platform offers you something no other conference provider can, qualified forward-looking data on what investors are looking for. This data is one of several ingredients in RESI's secret sauce that enables us to make so many meaningful connections (over 1500 per event!) between fundraising executives and investors...

By James Huang, Research Analyst, LSN

The CFDA released a set of proposals on May 11th regarding major reforms in the Chinese regulatory and approval system. The series of proposals is designed to accomplish four major goals:

  1. Acceleration of Drug/Medical Device Review/Approval Process
  2. Reform of Clinical Trials Management
  3. Implementation of a drugs/medical devices lifecycle management system.
  4. Protect drug and medical devices innovators' rights and interests.
From the many proposals presented, two key points stand out as potentially having a major impact on life science startups outside of China...

By Christine A. Wu, Senior Research Analyst, LSN

Investors in venture philanthropy, such as foundations and specific family offices, have deep expertise that is often overlooked. Many venture philanthropic groups have a specific mission in a disease area that provides them enormous capacity to bring forward more than any entrepreneur can realize. Along with funding, venture philanthropic investors can provide patient access for underserved populations, specialize in assessing and tracking "positively impactful" technology in their particular field, and utilize their own relationships with traditional ventures in creative ways, among other initiatives.

LSN is pleased to announce a panel of five expert venture philanthropic investors for the RESI San Diego Conference on June 19th. The audience will have an exclusive opportunity to hear from:
  • Evelia Johnston, Associate Director, Research Partnerships, The Michael J. Fox Foundation for Parkinson's Research
  • Debra Miller, Founder, CureDuchenne
  • Javeed Froozan, VP, Research Business Development & Strategic Alliances, Leukemia & Lymphoma Society
  • Jonathan Behr, Managing Director, Juvenile Diabetes Research Foundation (JDRF)
  • Lucie Brujin, Chief Scientist, ALS Association